A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
about
HIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityMolecular dynamics study of HIV-1 RT-DNA-nevirapine complexes explains NNRTI inhibition and resistance by connection mutationsEffects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.The "Connection" Between HIV Drug Resistance and RNase HThe N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensSubunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study iThe effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceEffect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.Efavirenz stimulates HIV-1 reverse transcriptase RNase H activity by a mechanism involving increased substrate binding and secondary cleavage activity.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors.Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.HIV-1 Reverse Transcriptase Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and New Inhibitors with Innovative Mechanisms of Actions.Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.Effects of crystalline state and self-nanoemulsifying drug delivery system (SNEDDS) on oral bioavailability of the novel anti-HIV compound 6-benzyl-1-benzyloxymethyl-5-iodouracil in rats.
P2860
Q27670634-30E4E28E-2EB3-4664-B5A1-34E359004196Q28533996-924CC7ED-2996-4BAA-908D-E930DAFC074CQ30355077-6AF0794D-F518-4D76-860B-9767624C5ECDQ34058254-6034BB1A-FE34-43C5-8178-0BC97013C554Q34059119-7B7F3289-D2BA-4604-BFD1-3621F1A63E30Q34094395-3EC6A2F8-9612-4401-B19A-BCB1047C37EFQ34145448-F09572E9-9581-4A18-B29B-529F7B891B2AQ34313605-6C14BDD6-3E2E-442B-A12F-7352F8E9674BQ34352431-05D08C26-FAD7-4DFE-9BF4-39BD629B2559Q34681252-45B34A08-4243-4EC9-A2A4-22E1951FC6DAQ35004847-326A7697-6D5F-43A8-9189-6ABD15515F61Q35200596-9DE0CE3F-226B-4AF6-BF70-CE1728F32057Q35586639-B3F861DD-5EF8-4E1D-8D5F-5FE2218EE786Q35684111-CD9DE498-685A-4D92-B7F8-30A2D7BA61A5Q36292765-6AADEC81-E824-43FB-878D-CFD33AAA80CCQ36501787-F8E3B609-BD0F-43C8-A7A0-708A71791DD6Q36553113-EFDA5BF7-F481-4754-945D-CBCBF9FDE836Q37350895-63BC7171-00BE-4575-8D92-ABBF5AFF7E63Q37547275-3288EC2F-1B2B-4B8F-A6DA-DD0277C5B22EQ37859395-16C32CB0-289B-44E2-8AFF-9BAD59AB9FE5Q39599947-9B7748AF-2950-4434-823C-384B48238A5FQ40288242-3680C0A1-91BA-45A6-B527-1A6B91F9E9DBQ41040182-57162196-6F96-4515-AAAD-E7BB3F984C1BQ41879018-2B321AA0-F6EB-457B-B871-DE041AE918AAQ42170864-F417A856-C913-474C-B2D1-5FF49E543F39Q48608254-0CF1F6DD-FE2C-4335-92E7-A72CB8B43254
P2860
A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@ast
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@en
type
label
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@ast
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@en
prefLabel
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@ast
A novel molecular mechanism of ...... erse transcriptase inhibitors.
@en
P2860
P356
P1433
P1476
A novel molecular mechanism of ...... verse transcriptase inhibitors
@en
P2093
Galina N Nikolenko
Krista A Delviks-Frankenberry
P2860
P304
P356
10.1128/JVI.01545-09
P577
2010-03-10T00:00:00Z